

1FW 1646 \$

PTO/SB/21 (07-06)

Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

SEP 25 2006

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/042,644
Filing Date	January 8, 2002
First Named Inventor	Jacques F. BANCHEREAU
Art Unit	1646
Examiner Name	Gyan Chandra
Attorney Docket Number	AGT.10006NP

ENCLOSURES (Check all that apply)

- | | | |
|---|---|--|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment/Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement

<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation
Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____
<input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input type="checkbox"/> Other Enclosure(s) (please identify below): |
|---|---|--|
- Remarks: The Director is hereby authorized to charge any appropriate fees that may be required by this paper, and to credit any overpayment, to Deposit Account No. 50-3218. This paper is submitted in duplicate.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Hutchison Law Group PLLC		
Signature			
Printed name	Joshua T. Elliott		
Date	September 21, 2006	Reg. No.	43,603

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Jennie P. Snead	Date	September 21, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Patent
Attorney Docket No. AGT.10006NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jacques F. BANCHEREAU et al.

Application No.: 10/042,644

Group Art Unit: 1646

Filing Date: January 8, 2002

Examiner: Gyan Chandra

Title: Methods for Treating Autoimmune
Diseases in a Subject and In Vitro Diagnostic
Assays

Confirmation No.: 7691

FIFTH INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. A copy of each of the documents cited and required by 37 C.F.R. § 1.98 is enclosed.

To assist the Examiner, the documents are listed on the attached form PTO/SB/08. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

It is noted that the specification of cited U.S. Application Publication No. 2004/0067232 (U.S. Application No. 10/466,023) substantially corresponds to the specification of the present application (identified in the heading above) and that both of these applications claim priority to the same U.S. provisional application.

This Information Disclosure Statement is being submitted after the period specified in 37 C.F.R. § 1.97(b). Therefore, please charge the fee of \$180.00 as required by 37 C.F.R. § 1.97(c). Consideration of the information provided herein is respectfully requested.



The Director is hereby authorized to charge any appropriate fees that may be required by this paper, and to credit any overpayment, to Deposit Account No. 50-3218. This paper is submitted in duplicate.

Respectfully submitted,

HUTCHISON LAW GROUP PLLC

Date:

September 21, 2006

By:

Joshua T. Elliott

Joshua T. Elliott

Registration No. 43,603

P.O. Box 31686
Raleigh, NC 27612
+1.919.829.9600

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on 09/21/2006

Jennie Snead


(Typed Name of Person Signing Certificate)

Jennie Snead

(Signature of Person Signing Certificate)

Date of Signing:

09/21/2006

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/042,644
		Filing or 371(c) date	January 8, 2002
		First Named Inventor	BANCHEREAU, Jacques
		Group Art Unit	1646
		Examiner Name	Gyan Chandra
Sheet 1 of 2		Attorney Docket No: AGT.10006NP	

US PATENT DOCUMENTS			
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document
	US- 2004/0067232	04/08/2004	Banchereau et al.
	6 291 661	09/18/2001	Graddis et al.

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Foreign Document No	Publication Date	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Abstract, Translation, English Language Equivalent or Search Report

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Abstract, Translation, English Language Equivalent or Search Report
	ANDRIANI, A., et al., "Autoimmune hemolytic anemia during alpha interferon treatment in nine patients with hematological diseases", Haematologica, May-June 1996, pp. 258-260, vol. 81, no. 3.	Abstract only
	BATOCCHI, A.P., et al., "Myasthenia gravis during interferon alfa therapy", Neurology, Feb. 1995, p. 382-383, vol. 45, no. 2.	Abstract only
	BOHBOT, N.L., et al. "Interferon-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves, disease", Eur. J. Endocrinol., Mar. 2006, pp. 367-372, vol. 154, no. 3.	Abstract only
	BROD, Staley A., "Ingested Type I Interferon: State of the Art as Treatment for Autoimmunity", Exp Biol Med, 2002, pp.981-988, vol. 227.	
	CHIEUX, V., et al., "Increased levels of antiviral MxA protein in peripheral blood of patients with chronic disease of unknown etiology", J. Med. Virol., Oct. 2001, pp. 301-308, vol. 65, no. 2.	Abstract only
	LANDAU, A., et al., "Acute autoimmune hemolytic anemia during interferon-alpha therapy for chronic hepatitis C", Dig. Dis. Sci., July 1999, pp. 1366-1367, vol. 44, no. 7	
	NGO, J. T., et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", The Protein Folding Problem and Tertiary Structure Prediction, 1994, pp. 491-495,	
	MASON, A.J., "Functional Analysis of the Cysteine Residues of Activan A", Molecular Endocrinology, 1994, pp. 325-332, vol. 8, no. 3.	
	HRON, J.D., et al., "Type I IFN Protects Against Murine Lupus", Journal of Immunology, 2004, pp. 2134-2142, vol. 173.	
	MURAKAMI T., et al., "Prediction of interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C.", J. Gastroenterol Hepatol., Sept.-Oct. 1995, p. 528-31, vol. 10, no. 5.	Abstract only


EXAMINER

DATE CONSIDERED

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/042,644
Filing or 371(c) date	January 8, 2002
First Named Inventor	BANCHEREAU, Jacques
Group Art Unit	1646
Examiner Name	Gyan Chandra

Sheet 2 of 2

Attorney Docket No: AGT.10006NP

	OISHI, A., et al., "Retinopathy is not the only ocular symptom: myasthenia gravis in association with interferon therapy", British Journal of Ophthalmology, 2005, pp. 1542-1543, vol. 89.	Abstract only
	RIZZI, R., et al. "Autoimmune hemolytic anemia presenting during treatment of chronic hepatitis C with interferon alpha", Apr-June 2003, p. 107-110, vol. 18, no. 2.	Abstract only
	STEWART, T.A. et al. "Induction of type I diabetes by interferon-alpha in transgenic mice", Science, June 25, 1993, p1942(5), vol. 260, no. 5116.	
	SKURKOVICH, S., et al. "A Disturbance of Interferon Synthesis with the Hyperproduction of Unusual Kinds of Interferon can trigger Autoimmune Disease and Play a pathogenic Role in AIDS: The Removal of These Interferons can be Therapeutic", Medical Hypothesis, 1994, p. 27-35, vol 42	
	VAN NOORT, J.M., et al., "Cell Biology of Autoimmune Diseases", International Review of Cytology 1998, pp. 127-206, vol. 178.	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached